Vigonvita Life Sciences Co Ltd
02630
Company Profile
Business description
Vigonvita Life Sciences Co Ltd biopharmaceutical company. It is engaged in the discovery, acquisition, development, and commercialization of small-molecule drugs in strategically focused therapeutic areas, namely neuropsychiatry, reproductive health, and viral infection. The company's core Products include LV232, for the treatment of depressive disorder, and TPN171, for the treatment of erectile dysfunction. The company’s operations are located in the PRC and Uzbekistan. Revenue is generated from the out-licensing and the sales of its pharmaceutical products.
Contact
No. 108, Yuxin Road
8th Floor, Building A
Suzhou Industrial Park District
Suzhou215123
CHNT: +86 51262898861
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
280
Stocks News & Analysis
stocks
Chart of the Week: Has gold reached bear market territory?
Investors are facing a shifting landscape.
stocks
Fair value upgrade for this ASX income player
Headwinds in listed energy stocks likely to have passed
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,885.60 | 59.90 | 0.68% |
| CAC 40 | 7,961.80 | 144.86 | 1.85% |
| DAX 40 | 23,190.98 | 510.94 | 2.25% |
| Dow JONES (US) | 46,341.51 | 1,125.37 | 2.49% |
| FTSE 100 | 10,369.23 | 192.78 | 1.89% |
| HKSE | 25,294.03 | 505.89 | 2.04% |
| NASDAQ | 21,590.63 | 795.99 | 3.83% |
| Nikkei 225 | 53,739.68 | 2,675.96 | 5.24% |
| NZX 50 Index | 12,825.87 | 86.24 | -0.67% |
| S&P 500 | 6,528.52 | 184.80 | 2.91% |
| S&P/ASX 200 | 8,671.80 | 53.10 | 0.62% |
| SSE Composite Index | 3,948.55 | 56.69 | 1.46% |